Celsius Therapeutics

Celsius Therapeutics is a biotechnology startup based in Cambridge, Mass., founded in 2018. The company's mission, as reflected in its slogan, is to leverage the power of single cell genomics to discover novel drug targets and precision therapeutics. Celsius Therapeutics aims to develop life-changing medicines by integrating data, experience, and insight using single-cell RNA sequencing and genomic analysis. In March 2022, the company secured an impressive $83.00M Series B investment. This round was led by a consortium of prominent investors including Amgen Ventures, Casdin Capital, GV, Cowin Venture, Alexandria Venture Investments, Amplitude Ventures, Catalio Capital Management, Section 32, Curie.Bio, and Fast Track Initiative, Inc. This substantial investment attests to the confidence that these established investors have in Celsius Therapeutics' potential for growth and success in driving innovation within the biotechnology and healthcare industries. Celsius Therapeutics' commitment to attracting, retaining, and nurturing top-tier talent underscores its dedication to achieving its goals. The company's emphasis on a rigorous, fast-paced, and collaborative environment, fostering innovation, teamwork, and excellence, reflects its drive to make a tangible impact on the future of healthcare. As Celsius Therapeutics continues to pursue its mission, it presents an intriguing opportunity for investors looking to support groundbreaking advancements in precision therapeutics and drug discovery.